Dutch researchers found that F-18 florbetaben amyloid PET resulted in suspected etiological diagnosis changes among 24.7% of patients with mild cognitive impairment, more of whom had negative PET scans, as well as treatment changes among 24.3% of patients, with changes more likely among those with positive scans. The findings in JAMA Neurology suggest that amyloid PET improves accuracy of MCI diagnosis and may inform patient and family decisions on medication use, clinical trial participation, employment and finances, according to an accompanying editorial.
F-18 florbetaben amyloid PET may prompt MCI diagnosis, treatment changes
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.